How lung capillary surface area changes after balloon pulmonary angioplasty for CTEPH
Assessment of Recovery of Functional Capillary Surface Area in Patients Undergoing a Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension
This will test whether balloon pulmonary angioplasty restores downstream functional pulmonary capillary surface area in people with chronic thromboembolic pulmonary hypertension.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Jewish General Hospital Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT05719415 on ClinicalTrials.gov |
What this trial studies
Researchers will measure functional pulmonary capillary surface area (FCSA) in people with CTEPH immediately before and after a session of balloon pulmonary angioplasty (BPA). The measurement uses trace quantities of 3H-benzoyl Phe-Ala-P to quantify capillary metabolic surface area in the lung. The protocol captures acute changes in downstream microvasculature associated with opening obstructed pulmonary artery segments. The single-center study is conducted at the Jewish General Hospital and excludes patients on ACE inhibitors or ARBs and those with a patent foramen ovale.
Who should consider this trial
Good fit: Ideal candidates are people with CTEPH who are eligible for BPA and who are not taking ACE inhibitors or ARBs and do not have a patent foramen ovale.
Not a fit: Patients with predominantly distal small-vessel disease not reachable by BPA, or those excluded for taking ACE inhibitors/ARBs or having a patent foramen ovale, are unlikely to receive benefit from the procedure or the measurements.
Why it matters
Potential benefit: If successful, this could clarify how much pulmonary microvasculature is recovered with BPA and help tailor treatment plans to improve outcomes.
How similar studies have performed: BPA has documented hemodynamic benefits in many CTEPH patients, but applying this tracer-based FCSA measurement in humans is a relatively novel technique that has not been widely used to quantify microvascular recovery.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension Exclusion Criteria: * Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, * Presence of patent foramen ovale
Where this trial is running
Montreal, Quebec
- David Langleben — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Study coordinator: David Langleben, MD
- Email: david.langleben@mcgill.ca
- Phone: 5143407531
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.